File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.bpobgyn.2011.11.009
- Scopus: eid_2-s2.0-84860214212
- PMID: 22285526
- WOS: WOS:000303634400007
- Find via
Supplementary
- Citations:
- Appears in Collections:
Article: Gestational trophoblastic disease
Title | Gestational trophoblastic disease |
---|---|
Authors | |
Keywords | Placental site trophoblastic tumour Hydatidiform mole Gestational trophoblastic meoplasia Fertility preservation Choriocarcinoma |
Issue Date | 2012 |
Publisher | Bailliere Tindall. The Journal's web site is located at http://www.elsevier.com/locate/bpobgyn |
Citation | Best Practice & Research: Clinical Obstetrics & Gynaecology, 2012, v. 26 n. 3, p. 357-370 How to Cite? |
Abstract | Most women with gestational trophoblastic disease are of reproductive age. Because the disease is readily treatable with favourable prognosis, fertility becomes an important issue. Hydatidiform mole is a relatively benign disease, and most women do not require chemotherapy after uterine evacuation. A single uterine evacuation has no significant effect on future fertility, and pregnancy outcomes in subsequent pregnancies are comparable to that of the general population, despite a slight increased risk of developing molar pregnancy again. If women develop persistent trophoblastic disease, single or combined chemotherapy will be needed. Although ovarian dysfunction after chemotherapy is a theoretical risk, a term live birth rate of higher than 70% has been reported without increased risk of fetal abnormalities. Successful pregnancies have also been reported after choriocarcinoma. Only a few case reports have been published on fertility-sparing treatment in placental-site trophoblastic tumour, and the successful rate is about 67%. Women are advised to refrain from pregnancy for at least 6 months after a molar pregnancy, and at least 12 months after a gestational trophoblastic neoplasia. Most of the contraceptive methods do not have an adverse effect on the return of fertility. Finally, at least one-half of these women suffer from some form of psychological or sexual problems. Careful counselling and involvement of a multi-disciplinary team are mandated. © 2012 Elsevier Ltd. All rights reserved. |
Persistent Identifier | http://hdl.handle.net/10722/173373 |
ISSN | 2023 Impact Factor: 3.9 2023 SCImago Journal Rankings: 1.532 |
ISI Accession Number ID | |
References |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Tse, KY | en_US |
dc.contributor.author | Ngan, HYS | en_US |
dc.date.accessioned | 2012-10-30T06:29:42Z | - |
dc.date.available | 2012-10-30T06:29:42Z | - |
dc.date.issued | 2012 | en_US |
dc.identifier.citation | Best Practice & Research: Clinical Obstetrics & Gynaecology, 2012, v. 26 n. 3, p. 357-370 | en_US |
dc.identifier.issn | 1521-6934 | en_US |
dc.identifier.uri | http://hdl.handle.net/10722/173373 | - |
dc.description.abstract | Most women with gestational trophoblastic disease are of reproductive age. Because the disease is readily treatable with favourable prognosis, fertility becomes an important issue. Hydatidiform mole is a relatively benign disease, and most women do not require chemotherapy after uterine evacuation. A single uterine evacuation has no significant effect on future fertility, and pregnancy outcomes in subsequent pregnancies are comparable to that of the general population, despite a slight increased risk of developing molar pregnancy again. If women develop persistent trophoblastic disease, single or combined chemotherapy will be needed. Although ovarian dysfunction after chemotherapy is a theoretical risk, a term live birth rate of higher than 70% has been reported without increased risk of fetal abnormalities. Successful pregnancies have also been reported after choriocarcinoma. Only a few case reports have been published on fertility-sparing treatment in placental-site trophoblastic tumour, and the successful rate is about 67%. Women are advised to refrain from pregnancy for at least 6 months after a molar pregnancy, and at least 12 months after a gestational trophoblastic neoplasia. Most of the contraceptive methods do not have an adverse effect on the return of fertility. Finally, at least one-half of these women suffer from some form of psychological or sexual problems. Careful counselling and involvement of a multi-disciplinary team are mandated. © 2012 Elsevier Ltd. All rights reserved. | en_US |
dc.language | eng | en_US |
dc.publisher | Bailliere Tindall. The Journal's web site is located at http://www.elsevier.com/locate/bpobgyn | en_US |
dc.relation.ispartof | Best Practice & Research: Clinical Obstetrics & Gynaecology | en_US |
dc.subject | Placental site trophoblastic tumour | en_US |
dc.subject | Hydatidiform mole | en_US |
dc.subject | Gestational trophoblastic meoplasia | en_US |
dc.subject | Fertility preservation | en_US |
dc.subject | Choriocarcinoma | en_US |
dc.subject.mesh | Antineoplastic agents - adverse effects - therapeutic use | - |
dc.subject.mesh | Fertility preservation | - |
dc.subject.mesh | Gestational trophoblastic disease - complications - psychology - therapy | - |
dc.subject.mesh | Neoplasm recurrence, Local - therapy | - |
dc.subject.mesh | Organ sparing treatments | - |
dc.title | Gestational trophoblastic disease | en_US |
dc.type | Article | en_US |
dc.identifier.email | Tse, KY: tseky@hkucc.hku.hk | en_US |
dc.identifier.email | Ngan, HYS: hysngan@hkucc.hku.hk | - |
dc.identifier.authority | Ngan, HYS=rp00346 | en_US |
dc.description.nature | link_to_subscribed_fulltext | en_US |
dc.identifier.doi | 10.1016/j.bpobgyn.2011.11.009 | en_US |
dc.identifier.pmid | 22285526 | - |
dc.identifier.scopus | eid_2-s2.0-84860214212 | en_US |
dc.identifier.hkuros | 198820 | - |
dc.relation.references | http://www.scopus.com/mlt/select.url?eid=2-s2.0-84860214212&selection=ref&src=s&origin=recordpage | en_US |
dc.identifier.volume | 26 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.spage | 357 | en_US |
dc.identifier.epage | 370 | en_US |
dc.identifier.isi | WOS:000303634400007 | - |
dc.publisher.place | United Kingdom | en_US |
dc.identifier.scopusauthorid | Ngan, HYS=34571944100 | en_US |
dc.identifier.scopusauthorid | Tse, KY=8876026900 | en_US |
dc.identifier.issnl | 1521-6934 | - |